Skip to main content
logo
Iovance Biotherapeutics, Inc. (FRA:2LB)
Germany flag Germany · Delayed Price · Currency is EUR
2.166
-0.102 (-4.50%)
At close: Jan 30, 2026

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Autologous Tumor Infiltrating Lymphocyte Cell Therapies
164.07M
Autologous Tumor Infiltrating Lymphocyte Cell Therapies Growth
13698.99%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
United States
161.04M
United States Growth
13444.41%
Rest of World
3.03M